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Introduction and Aims: All guidelines recommend an arteriovenous fistula (AVF) as
preferred bloodstream access. Still, many patients in Europe receive haemodialysis
(HD) via a permanent catheter. This ERBP initiated study explored potential barriers
related to attitude, organisation and reimbursement that may explain non-adherence to
this fistula-first (FF) policy.
Methods:We developed an electronic survey with 35 items regarding factors
potentially affecting choice and quality of HD access. Via national renal societies, we
invited 61 experts from 37 countries in the ERA-EDTA community to provide national
data on access preference, care delivery and reimbursement.
Results: In total, 44 experts (72% response rate) from 33 countries participated. The
majority were nephrologists (89%) from public centres (86%) with ≥15 years of clinical
experience (75%). AttitudeMany respondents (84%) believed that a FF policy was
justified by the current evidence base. However, only 36% expected an AVF to be a
durable access in >80% of prevalent HD patients. When being presented different
clinical cases, experts from 29 countries indicated that an AVF would be attempted in
>80% of 40-yr old patients without comorbidities. In 9 countries this was believed to be
the case in 75-yr olds with comorbidities. A FF policy was promoted in 23 countries.
Organisation Centralisation of HD access care was formally facilitated by service
providers in 4 countries; this was informally arranged by groups of centres in 18
countries, and not at all in 11. The time between the request and the actual procedure
for AVF creation was longer than for catheter placement in 21 countries and similar in
12. In many countries nephrologists were among those responsible for placing
catheters (n=24), but this was seldom so for creating AVFs (n=7). Educational meetings
on HD access were organised in 27 countries; 2 provided certified training. In 17
countries there was a formal multidisciplinary approach to HD access care in at least
part of the centres. Reimbursement In 19 countries facilities received a fee per created
access. In 13 of them the fee for AVF creation was higher than for placing permanent
catheters; in 5 this fee was paid directly to clinicians.
Conclusions: Our study showed a positive overall attitude towards a FF policy, which
became less apparent when applied to older and sicker patients. Future guidelines
should thus be more specific about which patients could benefit from this policy.
Reimbursement seemed to favour AVF. Besides limited access to dedicated and
certified clinicians to create AVFs, we identified lack of formal care centralisation as a
potential organisational barrier. Encouraging collaboration in HD access care might be
warranted.
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Introduction and Aims: Tunnelled central venous catheters (TCVC) are considered
inferior to fistulas and grafts in all nephrology guidelines. However, they, are being
increasingly used as haemodialysis vascular access. The purpose of this study was to
document the natural history of TCVC to determine the rate and type of catheter
replacement.
Methods: This was a prospective study of patients who are undergoing hemodialysis
(HD) with TCVC on our renal unit between January 2008 and December 2012.
Standard protocols, according to European Renal Best Practice (2007, 2010), detailing
all aspects of preventive nursing care, early diagnosis, were well established. All
catheters were inserted in the internal jugular vein (right 91 %). Complete data was
available on 141 patients (age 73 ± 10 year) who used 154 TCVC. Criteria for catheter
removal were (1) persistent bloodstream infection (repetitive blood culture 1 week after
completation of antibiotic therapy); (2) detection of an outbreak of CRBS; or (3)
catheter dysfunction (inadequate blood flow rate - Qb < 250 ml/min) for three
consecutive treatments. Event rates were calculated per 1,000 catheter days; TCVC
cumulative survival was estimated according Kaplan Meier analysis.
Results: Catheter replacement occurred in 15 patient (0.29 per 1,000 days), catheter
dysfunction with loss of patency was the main cause of replacement (0.18 per 1.000
days), typically within 12 months of catheter insertion. A total of 53 CRBS events in 36
patients were identified (0.82 per 1,000 days) There were 17 organisms isolated. The
most common organisms were Gram-positive, comprising 62% of all species. Among
Gram-positive pathogen isolated, most frequently were the Staphylococcus
Epidermidis of which 87% MRSE, the Enterococcus of which 85% E. faecalis, the
Staphylococcus Aureus of which 14% MRSA. Among Gram-negative (58% ESBL
positive) most frequently were pseudomoniacee and enterobacteriacee. The vast
majority of CVC infections (87%) were cleared by systemic antibiotics associated with
lock therapy. TCVC cumulative survival was 91% at 1 year, 88 % at 2 years and 85 % at
4 years.
Conclusions: Our data showed an high survival rate of TCVC in patient undergoing
HD, with low incidence of catheter dysfunction and CRBS. Careful application of
standard protocols in the dialysis staff contributed to achieve this results. These data
justify TCVC use for hemodialysis vascular access, even as a first choice, especially in
patients with exhausted peripheral access, abrupt failure or lack of a native
arteriovenous fistula and in patientswith limitedlife expectancy.
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Introduction and Aims: Catheter related bacteraemia (CRB) is a cause of significant
morbidity in patients maintained on long-term tunnelled haemodialysis catheters for
vascular access. Catheter salvage (antibiotic treatment without removal of the catheter)
is advocated for individuals without signs of systemic sepsis, who have a favourable
initial response to antibiotics. The study was designed to assess the hypothesis that
taurolidine-heparin-citrate (THC) line locks are superior to heparin in preventing
recurrence of CRB.
Methods: An open-label parallel-group randomised controlled trial was designed
comparing THC (containing heparin 500units/ml) against heparin (5000units/ml) line
locks. All patients on established haemodialysis within our in-centre and satellite
dialysis units, with evidence of a CRB and who had commenced treatment for catheter
salvage were considered eligible. Patients were randomised within two weeks of a
bacteraemia to either THC or heparin line locks following each dialysis for 6 months,
in addition to standard antibiotic therapy. The pre-specified primary outcome measure
was bacteraemia free catheter survival. (Clinical Trial No: NCT01243710).
Results: 27 patients were recruited to the study with 13 patients randomised to heparin
and 14 to THC. A significant difference in the primary outcome measure was seen with
improved catheter survival in individuals receiving THC (p=0.009). No recurrence of
CRB occurred in the THC group, while 5 catheters were removed in the heparin group
during the six month trial period. The trial size was too small to meaningfully interpret
pre-defined secondary outcome measures, though there was an increased thrombolytic
use in the THC arm.
Conclusions: Despite the small study size, THC line locks appear to be beneficial in
the prevention of recurrence of CRB. It is uncertain whether this is at the expense of
catheter dysfunction at a later point. THC line locks should be used as an adjunctive
therapy in the setting of catheter salvage, while their role as a standard line lock
remains unclear.
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Introduction and Aims: The objective monitoring of VA function should be
performed by measuring the blood flow (QA) (EBPG-2007). We have previously
reported that the VA function is impaired (lower QA values) in patients (pts) with
medial histological calcifications on the feeding artery (CKJ 2008; 1suppl 2: ii352). On
the other hand, fetuin-A is a potent inhibitor of vascular calcification and, according to
Chen et al (Am J Kidney Dis 2010; 56:720), is a predictor for VA patency. The aims of
this prospective observational study were to investigate the relationship between serum
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